HealthTree University: Therapies On The Horizon - ABBV-383

ABBV-383 is a promising drug that works as a bi-specific antibody designed to bring the immune system to cancer cells, specifically plasma cells. It's currently being studied in a phase one trial and has shown effectiveness at a recommended dose of 60 milligrams. Watch the video below for more information on how it works, its side effects, dosing, and administration. You can watch the whole course at HealthTree University.

ABBV-383

We’d like to thank our faculty who donated their time in creating these videos, including:

• Marcella Kaddoura, MD
• Muzaffar Qazilbash, MD

Want more?

We have over 500 HealthTree University videos online at HealthTree University! Learn the basics (and the not-so-basics) of myeloma from some of the top myeloma doctors in the world!

• Myeloma Basics Part 1
• Myeloma Basics Part 2
• Myeloma Basics Part 3
• Myeloma Care Basics
• Building Your Healthcare Team
• Becoming an Empowered Patient
• Starting Myeloma Treatment
• Know Your Therapy
• Know Your Labs: Blood and Urine Testing in Myeloma
• Autologous Stem Cell Transplant (ASCT)
• Precursor Conditions
• Relapsed and Refractory MM Treatment
• Classes of Drugs
• Immunotherapy
• Myeloma Bone Disease
• Imaging in Myeloma
• MRD Testing
• Basic Genetics and Cancer Biology
• Myeloma Genetics
• Types of Genetic Testing in Myeloma
• Specific Myeloma Genetics Mutations and Risk
• Precision Medicine
• Financial Advice for Myeloma Patients and Their Families
• Geriatric Care and Myeloma
• Myeloma Kidney Disease
• Amyloidosis
• Myeloma Basics (Spanish)
• COVID-19 and Multiple Myeloma
• Complementary and Integrated Therapy
• Allogeneic Stem Cell Transplant
• Survivorship
• Clinical Trials
• Understanding Basic Blood Tests
• Myeloma Vaccines